Pictet Asset Management Holding SA Sells 35,594 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Pictet Asset Management Holding SA lessened its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 860,096 shares of the company's stock after selling 35,594 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.79% of Mirum Pharmaceuticals worth $35,565,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after acquiring an additional 357 shares in the last quarter. R Squared Ltd acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000. AlphaQuest LLC grew its position in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter. Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $189,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $215,000.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the transaction, the chief operating officer now directly owns 27,015 shares of the company's stock, valued at $1,156,782.30. This represents a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jolanda Howe sold 750 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now owns 2,926 shares of the company's stock, valued at approximately $125,291.32. This represents a 20.40 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 133,679 shares of company stock worth $6,007,081. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded down $1.20 on Friday, reaching $42.03. The stock had a trading volume of 641,598 shares, compared to its average volume of 518,440. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -20.81 and a beta of 1.00. The firm's 50-day moving average is $47.64 and its two-hundred day moving average is $43.95. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent research reports. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Buy" and an average price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.